Karyopharm files for bankruptcy, looks to merger with Ayrmid for life raft - BioSpace
BioSpace · Nov 2, 9:08 PM
Karyopharm, deep in debt, to sell itself in bankruptcy - BioPharma Dive
BioPharma Dive · Nov 2, 5:13 PM
Karyopharm, deep in debt, to sell itself in bankruptcy - Yahoo Finance
Yahoo Finance · Nov 2, 5:07 PM
Market reactionShares fell 83% on Nov 2.
Karyopharm sells XPOVIO (selinexor), an oral cancer drug approved for multiple myeloma and a type of lymphoma, and has asked FDA to approve it with ruxolitinib for myelofibrosis.
Karyopharm wants to add myelofibrosis to XPOVIO (selinexor), its approved oral XPO1 inhibitor; Phase 3 SENTRY met its spleen co-primary endpoint but not the symptom endpoint. FDA said in writing that SVR35 is a reasonably likely surrogate for accelerated approval, and whether it accepts the August 31 sNDA is the next step. The company is in financial distress, operating under a lender forbearance extended to November 1 that a refusal to file, or liquidity below $10 million, would end.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA accepts the myelofibrosis sNDA
Does FDA accept the sNDA for review, and with Priority Review?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Karyopharm's lenders extended their forbearance to November 1 while FDA decides whether to accept its sNDA for selinexor plus ruxolitinib in myelofibrosis; the company has warned it may not continue as a going concern
sNDA filed for selinexor plus ruxolitinib in myelofibrosis, but runway expires before FDA rules
Approved XPO1 inhibitor files for myelofibrosis on one co-primary met, one missed, with runway expiring at filing — approval path and survival both unresolved
SENTRY split readout — one co-primary met, one missed — leaves selinexor's myelofibrosis filing viable but approvability genuinely unresolved before cash runs out in Q3 2026
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Breast and gynecologic cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
11 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.